Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Identification and validation of SRY-box containing gene family member SOX30 methylation as a prognostic and predictive biomarker in myeloid malignancies

Fig. 2

Validation of SOX30 methylation in MDS/AML patients. a The genomic coordinates (GC) of SOX30 promoter region CpG island and primer locations. The panel plots the GC content as a percentage of the total. Each vertical bar in the bottom panel represents the presence of a CpG dinucleotide. Black horizontal lines indicate regions amplified by RQ-MSP primer pairs and BSP primer pairs. CpGplot (http://emboss.bioinformatics.nl/cgi-bin/emboss/cpgplot) and Methyl Primer Express v1.0 software were used for creating the figure. TSS: transcription start site; RQ-MSP: real-time quantitative methylation-specific PCR; BSP: bisulfite sequencing PCR. b SOX30 methylation level in controls and MDS/AML patients. SOX30 methylation level was examined by RQ-MSP. Low/Int and High indicated MDS subtypes based on the classification of IPSS risks. AML included de novo AML and sAML which indicated MDS-derived AML. Each was compared to controls. NS: no significance; *: P < 0.05; **: P < 0.01; ***: P < 0.001. c Correlation between SOX30 methylation level and expression level in AML patients. SOX30 methylation level and expression level were examined by RQ-MSP and RQ-PCR, respectively. The correlation analysis was conducted by Spearman test. d SOX30 expression level in SOX30 hypermethylated and non-hypermethylated AML patients. SOX30 methylation level and expression level were examined by RQ-MSP and RQ-PCR, respectively. e SOX30 methylation density in controls and representative AML patients. SOX30 methylation density was determined by BSP. P1-P2 indicated two controls selected randomly. P3-P4 represented two AML patients with lower SOX30 methylation level. P5-P8 showed four AML patients with highest SOX30 methylation level

Back to article page